Clinical Trial Update: Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC [Phase 2]

View source ↗

Summary

Phase 2 study of combining transarterial chemoembolization with sorafenib for unresectable hepatocellular carcinoma was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: University of Pittsburgh | Conditions: Carcinoma, Hepatocellular | Phase 2 | Status: TERMINATED | Results posted: 2016-12-28